Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 11 July 2017

Indication(s)

Treatment of patients with moderate to severe Alzheimer’s disease.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Hyperammonaemia

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/002680
Orphan designation No
Date First Approved 22-04-2013
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Actavis Group PTC ehf.